VALIDITA DEL DILAZEP NEL TRATTAMENTO DELL'INSUFFICIENZA CORONARICA. STUDIO RANDOMIZZATO APERTO E IN DOPPIO CIECO IN SOGGETTI CON ANGINA STABILE DA SFORZO

Translated title of the contribution: Usefulness of dilazep in the treatment of chronic coronary insufficiency. Open and double-blind randomized study in subjects with effort angina

F. Rengo, M. Romano, L. De Caprio

Research output: Contribution to journalArticle

Abstract

The authors studied the effects of the dilazep (Cormelian Schering) in the medical management of coronary artery disease (CAD) patients by an open and double-blind study. The treatment consisted of 150 mg/day in the double-blind study and of 300 mg/day in the open study. We also compared the treatment of 150 mg/day versus 300 mg/day. The dilazep reduced the use of TNT and improved anginal pain. The exercise stress test demonstrated that dilazep reduces exercise-induced angina and improved electrocardiographic evidence of myocardial ischemia. A treatment of 300 mg/day gave better results than the treatment of 150 mg/day. It is concluded that dilazep represents useful medical management in the treatment of CAD patients.

Original languageItalian
Pages (from-to)489-494
Number of pages6
JournalMinerva Cardioangiologica
Volume28
Issue number7-8
Publication statusPublished - 1980

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this